DE69840106D1 - Formulierungen für amylin peptidagonisten mit insulin - Google Patents

Formulierungen für amylin peptidagonisten mit insulin

Info

Publication number
DE69840106D1
DE69840106D1 DE69840106T DE69840106T DE69840106D1 DE 69840106 D1 DE69840106 D1 DE 69840106D1 DE 69840106 T DE69840106 T DE 69840106T DE 69840106 T DE69840106 T DE 69840106T DE 69840106 D1 DE69840106 D1 DE 69840106D1
Authority
DE
Germany
Prior art keywords
approximately
formulations
insulin
amylin
peptidagonists
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69840106T
Other languages
German (de)
English (en)
Inventor
Italian James L
Shankar Musunuri
Cale Ruby
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amylin Pharmaceuticals LLC
Original Assignee
Amylin Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amylin Pharmaceuticals LLC filed Critical Amylin Pharmaceuticals LLC
Application granted granted Critical
Publication of DE69840106D1 publication Critical patent/DE69840106D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
DE69840106T 1998-01-09 1998-01-09 Formulierungen für amylin peptidagonisten mit insulin Expired - Lifetime DE69840106D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1998/000288 WO1999034822A1 (en) 1998-01-09 1998-01-09 Formulations for amylin agonist peptides

Publications (1)

Publication Number Publication Date
DE69840106D1 true DE69840106D1 (de) 2008-11-20

Family

ID=22266167

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69840106T Expired - Lifetime DE69840106D1 (de) 1998-01-09 1998-01-09 Formulierungen für amylin peptidagonisten mit insulin

Country Status (9)

Country Link
EP (1) EP1044015B1 (cg-RX-API-DMAC10.html)
JP (1) JP4353544B2 (cg-RX-API-DMAC10.html)
AT (1) ATE410182T1 (cg-RX-API-DMAC10.html)
AU (1) AU760609B2 (cg-RX-API-DMAC10.html)
CA (1) CA2365742C (cg-RX-API-DMAC10.html)
DE (1) DE69840106D1 (cg-RX-API-DMAC10.html)
DK (1) DK1044015T3 (cg-RX-API-DMAC10.html)
ES (1) ES2316161T3 (cg-RX-API-DMAC10.html)
WO (1) WO1999034822A1 (cg-RX-API-DMAC10.html)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69740096D1 (de) 1996-08-08 2011-02-17 Amylin Pharmaceuticals Inc Pharmazeutische Zusammensetzung mit einem Exendin-4-Peptid
US5783556A (en) * 1996-08-13 1998-07-21 Genentech, Inc. Formulated insulin-containing composition
US7312196B2 (en) * 1997-01-08 2007-12-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
JP4647736B2 (ja) * 1999-09-30 2011-03-09 小林製薬株式会社 薬剤発散具
EP2036539A1 (en) 2007-09-11 2009-03-18 Novo Nordisk A/S Stable formulations of amylin and its analogues
CN101822822A (zh) * 2009-03-04 2010-09-08 北京德众万全药物技术开发有限公司 一种普兰林肽的药物组合物及其制备方法
JP2009149684A (ja) * 2009-03-11 2009-07-09 Amylin Pharmaceut Inc アミリン作動薬ペプチド用製剤
CN102145164B (zh) * 2010-12-16 2013-02-27 深圳市健元医药科技有限公司 一种更加稳定的iapp类似物注射剂
US9399065B2 (en) 2012-04-16 2016-07-26 Biodel Inc. Magnesium compositions for modulating the pharmacokinetics and injection site pain of insulin
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
HUE035803T2 (en) 2012-12-21 2018-05-28 Sanofi Sa Dual GLP1 / GIP or trigonal GLP1 / GIP / glucagon agonists
TW201609797A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重glp-1/升糖素受體促效劑
WO2015086730A1 (en) 2013-12-13 2015-06-18 Sanofi Non-acylated exendin-4 peptide analogues
WO2015086728A1 (en) 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
EP3080154B1 (en) 2013-12-13 2018-02-07 Sanofi Dual glp-1/gip receptor agonists
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自exendin-4之雙重glp-1/升糖素受體促效劑
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽-4(Exendin-4)之肽類雙重GLP-1/升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重glp-1/昇糖素受體激動劑之艾塞那肽-4衍生物
WO2015168488A2 (en) 2014-05-02 2015-11-05 The Research Foundation For The State University Of New York Islet amyloid polypeptides with improved solubility
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
TW201706291A (zh) 2015-07-10 2017-02-16 賽諾菲公司 作為選擇性肽雙重glp-1/升糖素受體促效劑之新毒蜥外泌肽(exendin-4)衍生物
CN107952064B (zh) * 2016-10-14 2023-10-20 江苏豪森药业集团有限公司 含有聚乙二醇洛塞那肽的药物制剂及其制备方法
EP3562500B1 (fr) * 2016-12-27 2023-07-19 Adocia Compositions sous forme de solution aqueuse injectable comprenant de l'amyline, un agoniste au récepteur de l'amyline ou un analogue d'amyline et un co-polyaminoacide
WO2018144671A1 (en) 2017-02-01 2018-08-09 The Research Foundation For The State University Of New York Mutant islet amyloid polypeptides with improved solubility and methods for using the same
BR112020002804A2 (pt) 2017-08-24 2020-07-28 Novo Nordisk A/S composição farmacêutica líquida, e, kit
US11110063B2 (en) 2017-08-25 2021-09-07 MAIA Pharmaceuticals, Inc. Storage stable sincalide formulations
IL294521A (en) 2020-02-18 2022-09-01 Novo Nordisk As glp-1 compounds and their uses
AU2021399904B2 (en) * 2020-12-16 2024-09-05 Zealand Pharma A/S Pharmaceutical composition of glp-1/glp-2 dual agonists
IL312600B2 (en) 2022-05-30 2025-12-01 Zealand Pharma As Liquid formulations of amylin analogs

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4654324A (en) * 1981-08-27 1987-03-31 Eli Lilly And Company Human proinsulin pharmaceutical formulations
US5321008A (en) * 1991-01-10 1994-06-14 Amylin Pharmaceuticals, Inc. Methods and compositions for treatment of diabetes mellitus, hypoglycemia, and other conditions
EP0567626B1 (en) * 1991-11-19 2001-09-19 Amylin Pharmaceuticals, Inc. Amylin agonist peptides and uses therefor
US6143718A (en) * 1995-06-07 2000-11-07 Amylin Pharmaceuticals, Inc. Treatment of Type II diabetes mellutis with amylin agonists
US7910548B2 (en) * 1997-06-06 2011-03-22 Amylin Pharmaceuticals, Inc. Methods for treating obesity

Also Published As

Publication number Publication date
JP2002511103A (ja) 2002-04-09
WO1999034822A1 (en) 1999-07-15
EP1044015A1 (en) 2000-10-18
DK1044015T3 (da) 2008-12-08
AU5909498A (en) 1999-07-26
CA2365742A1 (en) 1999-07-15
AU760609B2 (en) 2003-05-15
ES2316161T3 (es) 2009-04-01
JP4353544B2 (ja) 2009-10-28
ATE410182T1 (de) 2008-10-15
CA2365742C (en) 2013-04-30
EP1044015A4 (en) 2001-05-23
EP1044015B1 (en) 2008-10-08

Similar Documents

Publication Publication Date Title
EP1044015A4 (en) AMYLINE AGONIST PEPTIDE FORMULATIONS
US11872266B2 (en) Rapid-acting insulin compositions
CA2295140A1 (en) Stable insulin formulations
ES2569949T3 (es) Formulaciones farmacéuticas que comprenden un péptido complejado con una dicetopiperazina
CA2090422C (en) Pharmaceutical composition of florfenicol
HU202761B (en) Process for producing stabilized erythropoietin compositions
Duane et al. Distribution, turnover, and mechanism of renal excretion of amylase in the baboon
US20060275353A1 (en) Stable topical drug delivery compositions
WO2003101395A3 (en) Formulations for amylin agonist peptides
ES2089011T3 (es) Excipiente lipidico de administracion nasal y aplicacion topica.
SK282949B6 (sk) Stabilný vodný prostriedok, stabilný vodný roztok, výrobok, spôsob prípravy stabilného vodného prostriedku a sterilizovaná plniaca nádoba
JP2005538068A (ja) 高濃度のヒト成長ホルモン(hGH)とフェノールを含有する液剤
PT819010E (pt) Formulacao de proteina compreendendo factor viii ou factor ix de coagulacao numa solucao aquosa
KR100195348B1 (ko) 안정한 프로스타글란딘 e1-함유 주사제 조성물
ATE228005T1 (de) Pharmazeutische formulierungen aus corticotropin freisetzenden faktor mit verbesserter stabilitaet in fluessiger form
JP2003504346A5 (cg-RX-API-DMAC10.html)
US7423028B2 (en) Injectable pharmaceutical compositions comprising sodium diclofenac and β-cyclodextrin
CA1303992C (en) Stable injectable solutions of vinca dimer salts
KR100271671B1 (ko) 고농도 tcf 주사제
PT1305057E (pt) Composicao de biomateria microparticular para uso medicinal
US4963529A (en) Stable growth hormone releasing factor preparation
BR9803730A (pt) Preparados farmacêuticos de cilansetron estabilizados contra a racemização.
US4289783A (en) Etomidate-containing compositions
HU191538B (en) Process for producing pharmaceutical compositions containing acid additional salts of vinca-dimeres
JPS62153224A (ja) プラスミノゲン製剤

Legal Events

Date Code Title Description
8364 No opposition during term of opposition